Standard Chemotherapy for Myelomatosis: An Area of Great Controversy

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1975 • 3,051 citations

Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents

1984 • 667 citations

Rationale for the use of alternating non-cross-resistant chemotherapy.

1982 • 545 citations

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens

1969 • 512 citations

Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy

1990 • 389 citations

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

1979 • 378 citations

Treatment for Multiple Myeloma

1969 • 377 citations

VAD‐based regimens as primary treatment for multiple myeloma

1990 • 320 citations

Nephrotoxic Potential of Bence Jones Proteins

1991 • 304 citations

Plasma cell myeloma--new biological insights and advances in therapy

1989 • 299 citations

Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma

1980 • 269 citations

Plasma cell myeloma--new biological insights and advances in therapy

1989 • 263 citations

Treatment of Renal Failure Associated With Multiple Myeloma

1990 • 241 citations

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

1977 • 222 citations

[Renal failure in multiple myeloma].

1986 • 221 citations

INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION

1989 • 204 citations

INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA

1989 • 198 citations

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

1988 • 163 citations

Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study [see comments]

1990 • 160 citations

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.

1983 • 156 citations

Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study [see comments]

1990 • 150 citations

Ploidy and proliferative characteristics in monoclonal gammopathies

1982 • 149 citations

High Serum Levels of Lactic Dehydrogenase Identify a High-Grade Lymphoma-like Myeloma

1989 • 142 citations

The growth fraction of human myeloma cells

1981 • 139 citations

Combination therapy for multiple myeloma

1977 • 137 citations

Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors

1990 • 130 citations

Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland.

1989 • 129 citations

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.

1991 • 129 citations

Changing clinical presentation of multiple myeloma

1991 • 125 citations

Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors

1990 • 101 citations

Improved survival of increased-risk myeloma patients on combined triple- alkylating-agent therapy: a study of the CALGB

1979 • 96 citations

Unmaintained remissions in multiple myeloma

1978 • 96 citations

REAPPRAISAL OF PLATEAU PHASE IN MYELOMA

1980 • 94 citations

Myeloma protein kinetics following chemotherapy

1982 • 94 citations

The survival time of patients with plasmocytic myeloma.

1960 • 91 citations

Chemotherapy for multiple myeloma

1984 • 90 citations

Bone marrow transplantation in multiple myeloma.

1991 • 87 citations

Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma

1982 • 85 citations

Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.

1972 • 82 citations

Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.

1989 • 76 citations

Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults.

1984 • 74 citations

Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells.

1990 • 73 citations

Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival

1990 • 70 citations

Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNU

1974 • 61 citations

Long‐term prognostic value of serum β₂ microglobulin in myelomatosis

1990 • 58 citations

Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients

1988 • 56 citations

Results of the mrc myelomatosis trials for patients entered since 1980

1988 • 53 citations

Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults

1985 • 52 citations

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan‐prednisone

1990 • 49 citations

Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP

1988 • 47 citations

Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?

1989 • 47 citations

Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma

1984 • 46 citations

Treatment comparisons in the third MRC myelomatosis trial.

1980 • 45 citations

Report on the second myelomatosis trial after five years of follow-up.

1980 • 42 citations

Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III —A randomized study from MGCS

1989 • 39 citations

Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure

1990 • 38 citations

Chemotherapy of myeloma: Drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma

1988 • 36 citations

Kinetics of circulating B lymphocytes in human myeloma

1983 • 36 citations

An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study.

1988 • 35 citations

Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients

1989 • 32 citations

Treatment of multiple myeloma with M-2 protocol and without maintenance therapy

1983 • 31 citations

Chemoimmunotherapy for multiple myeloma

1981 • 30 citations

Reassessment of the relationship between M-protein decrement and survival in multiple myeloma

1989 • 30 citations

Treatment of multiple myeloma with an intensive 5‐drug combination or intermittent melphalan and prednisone; a randomised multicentre trial

1987 • 26 citations

Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index.

1987 • 25 citations

Oral melphalan pharmacokinetics — relation to dose in patients with multiple myeloma

1989 • 25 citations

Phase III study of intermittent 5‐drug regimen (VBCMP) versus intermittent 3‐drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis

1985 • 24 citations

Dose Intensity Analysis of Melphalan and Prednisone in Multiple Myeloma

1988 • 23 citations

Treatment of multiple myeloma in old patients

1989 • 23 citations

Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.

1980 • 22 citations

Treatment of multiple myeloma: A randomized study of three different regimens

1985 • 21 citations

Multiple myeloma in the geriatric patient

1990 • 20 citations

Intermediate‐dose (25 mg/m²) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment

1989 • 19 citations

Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma

1991 • 18 citations

A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma

1990 • 17 citations

Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy

1990 • 17 citations

Newer approaches to the therapy of multiple myeloma [editorial]

1990 • 16 citations

GM-CSF-exposed peripheral blood progenitors as sole source of stem cells for autologous transplantation in two patients with multiple myeloma.

1990 • 16 citations

Early recruitment in the human myeloma cell population after cytostatic treatment.

1976 • 15 citations

Lack of Correlation between Plasma Cell Thymidine Labelling Index and Serum Beta-2-Microglobulin in Monoclonal Gammopathies

1987 • 15 citations

Oral dosage of melphalan and response to treatment in multiple myeloma

1990 • 15 citations

Newer approaches to the therapy of multiple myeloma [editorial]

1990 • 15 citations

Human Myeloma: Kinetics of the Remission Phase

1982 • 14 citations

Multiple myeloma in central and northern Norway 1981–1982: A follow‐up study of a randomized clinical trial of 5‐drug combination therapy versus standard therapy

1988 • 14 citations

Mouse Myeloma

1975 • 12 citations

Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma

1986 • 12 citations

Single-Dose Intravenous Melphalan in Advanced Multiple Myeloma

1990 • 9 citations

Chemotherapy of myeloma: Swog studies

1988 • 7 citations

Long Unmaintained Remission in Multiple Myeloma

1986 • 7 citations

Short Course Intermediate Dose Intravenous Melphalan Therapy in Myeloma Relation to Early Emergence of Drug Resistance (Phase II Study)

1987 • 7 citations

Oral Versus Intravenous Melphalan and Prednisone Treatment in Multiple Myeloma Stage II: A randomized study from the Myeloma Group of Central Sweden

1990 • 5 citations

Cell kinetics of multiple myeloma.

1987 • 4 citations

Is there a correct time to begin treatment of multiple myeloma?

1987 • 4 citations

Bone Marrow Transplantation in Multiple Myeloma

1991 • 1 citations